Teva Pharmaceutical (Germany) Today
TEV Stock | EUR 21.20 0.70 3.41% |
Performance11 of 100
| Odds Of DistressOver 53
|
Teva Pharmaceutical is trading at 21.20 as of the 22nd of December 2024. This is a 3.41 percent increase since the beginning of the trading day. The stock's lowest day price was 20.0. Teva Pharmaceutical has 53 percent odds of going through some form of financial distress in the next two years but had a very good returns during the last 90 days. The performance scores are derived for the period starting the 23rd of September 2024 and ending today, the 22nd of December 2024. Click here to learn more.
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. Teva Pharmaceutical Industries Limited was founded in 1901 and is headquartered in Petach Tikva, Israel. The company has 1.11 B outstanding shares. More on Teva Pharmaceutical Industries
Moving against Teva Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Teva Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Teva Pharmaceutical's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Teva Pharmaceutical or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Business Concentration | Drug Manufacturers - Specialty & Generic, Healthcare (View all Sectors) |
Teva Pharmaceutical Industries (TEV) is traded on Frankfurt Exchange in Germany and employs 34,004 people. The company currently falls under 'Large-Cap' category with a current market capitalization of 10.47 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Teva Pharmaceutical's market, we take the total number of its shares issued and multiply it by Teva Pharmaceutical's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Teva Pharmaceutical classifies itself under Healthcare sector and is part of Drug Manufacturers - Specialty & Generic industry. The entity has 1.11 B outstanding shares.
Teva Pharmaceutical Industries has accumulated about 1.97 B in cash with 1.59 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.81.
Check Teva Pharmaceutical Probability Of Bankruptcy
Ownership AllocationTeva Pharmaceutical shows a total of 1.11 Billion outstanding shares. 30% of Teva Pharmaceutical outstanding shares are owned by institutional holders. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Teva Ownership Details
Teva Pharmaceutical Risk Profiles
Although Teva Pharmaceutical's alpha and beta are two of the key measurements used to evaluate Teva Pharmaceutical's performance over the market, the standard measures of volatility play an important role as well.
Mean Deviation | 1.88 | |||
Semi Deviation | 1.46 | |||
Standard Deviation | 3.64 | |||
Variance | 13.27 |
Teva Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Teva Pharmaceutical without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Comparator Now
Portfolio ComparatorCompare the composition, asset allocations and performance of any two portfolios in your account |
All Next | Launch Module |
Teva Pharmaceutical Corporate Management
Elected by the shareholders, the Teva Pharmaceutical's board of directors comprises two types of representatives: Teva Pharmaceutical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Teva. The board's role is to monitor Teva Pharmaceutical's management team and ensure that shareholders' interests are well served. Teva Pharmaceutical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Teva Pharmaceutical's outside directors are responsible for providing unbiased perspectives on the board's policies.
Eli Shani | Ex Portfolio | Profile | |
David Stark | Ex Officer | Profile | |
Mark Sabag | Ex Commercial | Profile | |
Eric Drape | Ex Operations | Profile | |
Sven Dethlefs | Ex Commercial | Profile | |
Kevin Mannix | VP Relations | Profile | |
Eliyahu Kalif | Ex CFO | Profile |
Other Information on Investing in Teva Stock
Teva Pharmaceutical financial ratios help investors to determine whether Teva Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Teva with respect to the benefits of owning Teva Pharmaceutical security.